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VasopressinThe insular cortex (IC) has been reported to be involved in central cardiovascular control. In the present study,
we investigated the cardiovascular responses evoked by microinjection of noradrenaline into the IC as well as
the central and peripheral mechanisms involved in their mediation. Microinjection of noradrenaline into the
IC (3, 7, 10, 15, 30 and 45 nmol/100 nL) caused long-lasting dose-related pressor and bradycardiac responses.
The cardiovascular responses evoked by 15 nmol of noradrenaline were blocked by IC pretreatment with
WB4101 or 5-methyl-urapidil, selective α1-adrenoceptor antagonists. IC pretreatment with either the
selective α2-adrenoceptor antagonists RX821002 or the β-adrenoceptor antagonist propranolol did not affect
noradrenaline cardiovascular responses. Noradrenaline cardiovascular responses were mimicked by
microinjection of the selective α1-adrenoceptor agonist phenylephrine into the IC, thus reinforcing the
idea that α1-adrenoceptors mediate cardiovascular responses to noradrenaline microinjected into the IC. The
pressor response to noradrenaline microinjection was potentiated by i.v. pretreatment with the ganglion
blocker pentolinium and inhibited by i.v. pretreatment with the selective V1-vasopressin receptor antagonist
dTyr(CH2)5(Me)AVP. The bradycardiac response to noradrenaline microinjection into the IC was abolished by
pretreatment with either pentolinium or the V1-vasopressin receptor antagonist, indicating its reﬂex origin. In
conclusion, our results suggest that pressor response evoked by microinjection of noradrenaline into the IC
involve the activation of IC α1-adrenoceptors to cause the release of vasopressin into the circulation.logy, School of Medicine of
0, Ribeirão Preto, São Paulo,
a).
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It was assumed before the 1960s that rats did not have a cortical
structure analogous to the prefrontal cortex of primates (Rose and
Woolsey, 1948). However, Leonard (1969) described projections from
the dorsal medial thalamic nucleus to two distinct frontal cortex
regions of the rat brain that could be deﬁned as prefrontal cortex. The
prefrontal cortex is a limbic region, which integrates sensory and
visceral information from peripheral receptors and has been impli-
cated in control of autonomic activity (Anand and Dua, 1956; Delgado,
1960; Neafsey, 1990; Resstel and Correa, 2006). In rats, the prefrontal
cortex has been anatomically divided into two main regions: the
lateral prefrontal cortex or insular cortex (IC) and the medial
prefrontal cortex (mPFC) (Krettek and Price, 1977; Leonard, 1969).
The IC has been proposed to be involved in cardiovascular regulation
(Allen and Cechetto, 1995; Alves et al., 2009a, 2010; Ruggiero et al.,
1987). Its electrical or chemical stimulation has been reported to
cause either pressor or depressor responses (Allen and Cechetto,1995; Hardy and Holmes, 1988; Hardy and Mack, 1990; Ruggiero
et al., 1987; Yasui et al., 1991). Moreover, it has also been reported
that the IC modulates baroreﬂex activity in unanesthetized rats (Alves
et al., 2009a,b).
Cardiovascular responses have been reported after noradrenaline
microinjection into medullary structures such as the nucleus of the
solitary tract (Zandberg et al., 1979) as well as into supramedullary
structures such as the lateral septal area (Scopinho et al., 2006), the
amygdala (Ohta et al., 1991), hypothalamic nuclei (Busnardo et al.,
2009; Camargo et al., 1979; Harland et al., 1989) and the bed nucleus
of the stria terminalis (BST) (Crestani et al., 2008, 2007). These results
suggest that central noradrenergic pathways are involved in cardio-
vascular control.
There is evidence that noradrenergic terminals are present in the
prefrontal cortex (Morrison et al., 1979). These terminals originate
mainly in projections from the locus coeruleus (LC) and play an
important role in the regulation of cortical function (Morrison et al.,
1979; Sara and Segal, 1991; Ungerstedt, 1971). Moreover, noradren-
ergic neurotransmission in the prefrontal cortex has been implicated
in modulation of the cardiovascular system in stress-induced
situations (Funk and Stewart, 1996). We have previously reported
that such noradrenergic neurotransmission in the IC is involved in the
modulation of baroreﬂex activity (Alves et al., 2009a). However, the
91F.H.F. Alves et al. / Autonomic Neuroscience: Basic and Clinical 160 (2011) 90–98involvement of IC noradrenergic neurotransmission in the control of
arterial pressure and heart rate (HR) has never been systematically
investigated. Here, we report on the cardiovascular effects evoked by
noradrenaline microinjection into the IC. In addition, we studied the
subtypes of adrenoceptor activated in the IC as well as the peripheral
mechanism involved in the mediation of these cardiovascular effects.
2. Materials and methods
2.1. Animal preparation
Eighty-nine male Wistar rats weighing 230–270 g were used.
Animals were kept in the Animal Care Unit of the Department of
Pharmacology, School of Medicine of Ribeirão Preto, University of
São Paulo. Rats were housed in plastic cages under standard
laboratory conditions, with free access to food and water and under
a 12 h light/dark cycle (lights on at 06:30 h). The Institution's
Animal Ethics Committee approved the housing conditions and
experimental procedures (process number: 167/2007).
Five days before the experiment, the rats were anesthetized
with tribromoethanol (250 mg/kg, i.p.). After local anesthesia with
2% lidocaine, the skull was surgically exposed and stainless steel
guide cannulas (26 G) were implanted unilaterally in the IC, using a
stereotaxic apparatus (Stoelting, Wood Dale, Illinois, USA). Stereo-
taxic coordinates for cannula implantation in the IC were selected
from the rat brain atlas of Paxinos and Watson (1997) and were:
antero-posterior=+11.7 mm from interaural, lateral=4.0 mm
from the medial suture and vertical=−4.5 mm from the dorsal
surface of the skull. Cannulas were ﬁxed to the skull with dental
cement and one metal screw. After surgery, the animals were
treated with a poly-antibiotic preparation of streptomycins and
penicillins (i.m., 0.27 mg/kg, Pentabiotico, Fort Dodge®, Campinas,
SP, Brazil) to prevent infection, and with the non-steroidal anti-
inﬂammatory ﬂunixine meglumine (2.5 mg/kg, i.m.; Banamine®,
Schering Plough, Cotia, SP, Brazil) for post-operative analgesia.
One day before the experiment, the rats were anesthetized with
tribromoethanol (250 mg/kg, i.p.) and a catheter (a 4 cm segment of
PE-10heat-bound toa 13 cmsegmentof PE-50, ClayAdams, Parsippany,
NJ, USA) was inserted into the abdominal aorta through the femoral
artery, and later used for arterial pressure and HR recording. A second
catheter was implanted into the femoral vein for infusion of saline,
pentolininum or dTyr(CH2)5(Me)AVP. Both catheters were tunneled
under the skin and exteriorized on the animal's dorsum. After surgery,
the animals were treated with the non-steroidal anti-inﬂammatory
ﬂunixine meglumine (2.5 mg/kg, i.m.) for post-operative analgesia.
2.2. Measurement of cardiovascular responses
On the day of the experiment, the arterial cannula was connected
to a pressure transducer. Pulsatile arterial pressure of freely moving
animals was recorded with a HP-7754A preampliﬁer (Hewlett
Packard, Palo Alto, CA) and an acquisition board (MP100A; Biopac
Systems Inc., Santa Barbara, CA) connected to a computer. Mean
arterial pressure (MAP) andHR values were derived from the pulsatile
arterial pressure recordings and processed on-line. The sampling rate
utilized to acquisition of the data was 200 Hz.
2.3. Drug injection into the IC
The needles (33 G, Small Parts, Miami Lakes, FL, USA) used for
microinjection into the IC were 1 mm longer than the guide cannula
and were connected to a 1 μL syringe (7001-KH, Hamilton, Reno, NV,
USA) through PE-10 tubing. The needle was carefully inserted into the
guide cannula without restraining the animals and drugs were
injected in a ﬁnal volume of 100 nL over a 10 s period.2.4. Experimental protocols
After surgery, animals were kept in individual cages that later were
used in their transport to the experimental room. Animals were
allowed 60 min to adapt to the conditions of the experimental room,
such as sound and illumination, before starting arterial pressure and
HR recordings. The experimental room was acoustically isolated and
had constant background noise produced by an air exhauster to
minimize sound interference within the experimental room. At least
another 30 min period of basal recording of MAP and HR was allowed
before beginning experiments. Care was taken to start injections only
when blood pressure and HR values had stabilized.2.4.1. Cardiovascular responses to the microinjection of different doses of
noradrenaline into the IC of unanesthetized rats
Different doses of noradrenaline were microinjected into the IC of
unanesthetized rats. The doses used were 3, 7, 10, 15, 30, or 45 nmol
in 100 nL (n=5 for 7, 10, 15 and 30 nmol and n=4 for 3 and
45 nmol). To plot the dose–response curve, each animal received up
to two microinjections of noradrenaline into the IC. The interval
between microinjections was 24 h in order to avoid the tachyphylaxis
phenomenon and the dose microinjected in the ﬁrst and second day
was different. The ordering of the injections was alternated to
randomize experimental variable. For each dose in the curve, it was
calculated the mean of the effect produced in different animals. These
values were further plotted to produce the dose–effect curves.
The dose of 15 nmol of noradrenaline, that approximates the ED50,
was used when studying effects of different treatments on the
cardiovascular responses to noradrenaline microinjected into the IC. A
different group of animals was used to verify a possible tachyphylaxis
phenomenon. In this protocol, microinjections of noradrenaline
(15 nmol/100 nL, n=5) into the IC were repeated 30 min apart.2.4.2. Study of the local adrenoceptor involved on cardiovascular
response to noradrenaline microinjection into the IC
A group of animals was used to study the IC adrenoceptor involved
in noradrenaline responses. Twenty four hours after the ﬁrst
noradrenaline microinjection, different group of animals received
artiﬁcial cerebrospinal ﬂuid (ACSF) (100 nL, n=5) (Alves et al.,
2009a,b); selective α1-adrenoceptor antagonists WB4101
(15 nmol/100 nL, n=5) (Alves et al., 2009a) or 5-methyl-urapidil
(15 nmol/100 nL, n=5); the selective α2-adrenoceptor antagonist
RX821002 (15 nmol/100 nL, n=5) (Alves et al., 2009a) or the
nonselective β-adrenoceptor antagonist propranolol (15 nmol/
100 nL, n=5) (Alves et al., 2009a) injected into the IC. Noradrenaline
was again injected into the IC 10 min later. To conﬁrm the involvement
ofα1-adrenoceptor in themediation of responses to noradrenaline into
the IC, the selectiveα1-adrenoceptor agonist phenylephrine (200 nmol/
100 nL, n=5) (Correa and Peres-Polon, 1995) was microinjected into
the IC of a group of animals.2.4.3. Study of the peripheral mechanisms involved in the meditation of
the cardiovascular responses to noradrenaline microinjected into the IC
A group of rats were used to study the peripheral mechanisms
involved in the meditation of the cardiovascular responses to
noradrenaline microinjected into the IC. These experiments were
also carried out over 2 days. On day 1, noradrenaline (15 nmol/
100 nL) was microinjected into the IC as control. On the second day,
noradrenaline was injected into the IC 10 min after i.v. treatment with
saline (n=5), the ganglion blocker pentolinium (5 mg/kg, n=5)
(Alves et al., 2007; Moriguchi et al., 1998) or the V1-vasopressin
receptor antagonist dTyr(CH2)5(Me)AVP (50 μg/kg, n=5) (Alves
et al., 2007).
Fig. 1. Changes in mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by
noradrenaline microinjection (3, 7, 10, 15, 30, or 45 nmol/100 nL) into the IC of
unanesthetized rats (n=5 for 7, 10, 15 and 30 nmol and n=4 for 3 and 45 nmol).
Points represent means and bars the SEM. Dose–response curves were generated by
nonlinear regression analysis and were statistically signiﬁcant (ΔMAP, r2=0.91 and
ΔHR, r2=0.92).
Fig. 2. A — Typical recordings showing mean arterial pressure (MAP), pulsatile arterial
pressure (PAP) and heart rate (HR) changes in response to 15 nmol/100 nL of
noradrenaline microinjected into the IC of one unanesthetized rat. B — Typical
recordings showing MAP, PAP and HR changes in response to 200 nmol/100 nL of
phenylephrine microinjected into the IC of one unanesthetized rat.
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At the end of the experiment, animals were anesthetized with
urethane (1.25 g/kg i.p.) and 100 nL of 1% Evan's blue dye was
microinjected into the IC as a marker of the microinjection site.
Animals were submitted to intracardiac perfusion with 0.9% NaCl
followed by 10% formalin. The brains were removed and post-ﬁxed for
24 h at 4 °C, and 40-μm sections were cut with a cryostat (CM-1900;
Leica, Wetzlar, Germany). Brain sections were stained with 1% neutral
red for light microscopic analysis. Microinjection sites were identiﬁed
in serial sections according to the rat brain atlas of Paxinos and
Watson (1997).
2.6. Drugs
Noradrenaline HCl (SIGMA, St. Louis, MO, USA), dl-propranolol
(SIGMA); WB4101 (TOCRIS, Ellisvalle, MO, USA); RX821002 (TOCRIS);
5-methyl-urapidil (RBI, Natick, MA, USA) and phenylephrine (SIGMA)
were dissolved in artiﬁcial cerebrospinal ﬂuid (ACSF), which had the
following composition (in mmol/L): 100 NaCl; 2 Na3PO4; 2.5 KCl; 1.0
MgCl2; 27NaHCO3; 2.5 CaCl2 (pH=7.4). Pentoliniumbitartrate (SIGMA),
dTyr(CH2)5(Me)AVP (Peninsula Laboratories, King of Prussia, PA, USA),
tribromoethanol (SIGMA) and urethane (SIGMA) were dissolved in
saline (NaCl 0.9%). Flunixine meglumine (Banamine®, Schering Plough,
Brazil) and poly-antibiotic preparation of streptomycins and penicillins
(Pentabiotico®, Fort Dodge, Brazil) were used as provided.
2.7. Statistical analysis
Data are presented as means±S.E.M. Basal values of MAP and HR
before and after pharmacological treatment were compared using
paired Student's t-test. Nonlinear regression analysis was used to
compare MAP and HR responses after microinjection of different
doses of noradrenaline into the IC. Two-way ANOVA for repeated
measurements (treatment vs. time) was used to compare effects of the
treatments on MAP and HR responses observed after microinjection of
noradrenaline into the IC. Pb0.05 was assumed to be statistically
signiﬁcant.
3. Results
3.1. Cardiovascular responses to the microinjection of different doses of
noradrenaline into the IC of unanesthetized rats
Microinjection of ACSF (n=5) into the IC did not affect either MAP
(97±1 vs. 100±2mmHg, t=1.7, PN0.05) or HR (358±11 vs. 352±
13 bpm, t=0.3, PN0.05) baseline values. However, microinjection of
noradrenaline (3, 7, 10, 15, 30 and 45 nmol/100 nL) into the IC of
unanesthetized rats (basal MAP=99±1 and basal HR=369±16,
n=28) caused long-lasting dose-related pressor and bradycardiac
responses (Fig. 1). Nonlinear regression analysis indicated a signiﬁcant
correlationbetweendoses andeitherpressor (r2=0.91, df=26, Pb0.05)
or bradycardiac (r2=0.92, df=26, Pb0.05) responses. The ED50 was
approximately 15 nmol for cardiovascular responses. A typical recording
showing the cardiovascular effects evoked by the microinjection of
noradrenaline (15 nmol/100 nL) into the IC is presented in Fig. 2A.
The cardiovascular responses to the microinjection of noradren-
aline (15 nmol/100 nL) (n=5) into the IC were decreased when
a second microinjection of noradrenaline was made 30 min later
(MAP: F(1,392)=30, Pb0.0001 and HR: F(1,392)=32, Pb0.0001)
(Fig. 3). However, responses were not affected when noradrenaline
was microinjected 24 h after the ﬁrst injection (Fig. 3).
Microinjection of noradrenaline (15 nmol/100 nL) into structures
surrounding the IC, such as primary motor cortex (MAP before: 98±3
and after: 99±3mmHg, t=3, PN0.05; and HR before: 343±12 and
after: 341±12 bpm, t=1.2, PN0.05; n=3) and forceps minor of the
Fig. 3. Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC 30 min and 24 h after
the ﬁrst microinjection of noradrenaline. Noradrenaline injections were made at time 0. Points represent the mean and bars the SEM; two-way ANOVA followed by Bonferroni's post
hoc test.
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PN0.05; and HR before: 359±15 and after: 357±17 bpm; t=0.9,
PN0.05; n=3) had no effect on either MAP or HR.
3.2. Effect of IC pretreatment with ACSF, WB4101, 5-methyl-urapidil,
RX821002 or propranolol on cardiovascular responses to the
microinjection of noradrenaline into the IC of unanesthetized rats
3.2.1. ACSF
IC pretreatment with ACSF (n=5) did not affect either the pressor
(43±2 vs. 45±3 mm Hg, t=0.3, PN0.05) or the bradycardiac (50±2
vs. 49±3 bpm, t=0.2, PN0.05) response to noradrenaline micro-
injected into the IC of unanesthetized rats.
3.2.2. WB4101
The microinjection of the selective α1-adrenoceptor antagonist
WB4101 (n=5) into the IC did not affect eitherMAP (103±3 vs. 100±Fig. 4. Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) e
pretreatment with selectiveα1-adrenoceptor antagonistsWB4101 (15 nmol/100 nL) or 5-m
and bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test.3 mmHg, t=0.6, PN0.05) or HR (356±7 vs. 359±11 bpm, t=0.3;
PN0.05) baseline values. However, cardiovascular responses to the
microinjection of noradrenaline into the IC were signiﬁcantly reduced
after IC treatmentwithWB4101 (Fig. 4A). Two-way ANOVA indicated a
signiﬁcant effect of IC treatmentwithWB4101 on cardiovascular effects
of noradrenaline (MAP: F(1,392)=278, Pb0.0001; andHR: F(1.392)=237,
Pb0.0001); a signiﬁcant effect over time (MAP: F(48,392)=10,
Pb0.0001; and HR: F(48,392)=25, Pb0.0001) and an interaction
between treatment and time (MAP: F(48,392)=8, Pb0.0001; and HR:
F(48,392)=19, Pb0.0001) (Fig. 4A).
3.2.3. 5-Methyl-urapidil
The microinjection of the selective α1-adrenoceptor antagonist
5-methyl-urapidil (n=5) into the IC did not affect either MAP (95±2
vs. 100±3 mmHg, t=1.1, PN0.05) or HR (384±12 vs. 362±11 bpm,
t=1, PN0.05) baseline values. However, cardiovascular responses to the
microinjection of noradrenaline into the IC were signiﬁcantly reducedvoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after IC
ethyl-urapidil. Noradrenaline injections weremade at time 0. Points represent themean
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indicated a signiﬁcant effect of the treatmentwith 5-methyl-urapidil on
cardiovascular effects of noradrenaline (MAP: F(1,392)=74, Pb0.0001;
and HR: F(1.392)=4, Pb0.0001); a signiﬁcant effect over time (MAP:
F(48,392)=6, Pb0.0001; and HR: F(48,392)=4, Pb0.0001) and an
interaction between treatment and time (MAP: F(48,392)=1.5,
Pb0.0001; and HR: F(48,392)=1.1, Pb0.0001) (Fig. 4B).3.2.4. RX821002
Microinjection of the selective α2-adrenoceptor antagonist
RX821002 (n=5) into the IC did not affect either MAP (99±3
vs. 100±3 mm Hg, t=0.2, PN0.05) or HR (353±9 vs. 366±
12 bpm, t=2.1, PN0.05) baseline values. IC pretreatment with
RX821002 also did not change cardiovascular responses to the
microinjection of noradrenaline into the IC (Fig. 5). Two-way
ANOVA indicated no signiﬁcant effect of RX821002 on the
cardiovascular effects of noradrenaline (MAP: F(1,392)=0.2,
PN0.05; and HR: F(1.392)=0.2, PN0.05), but indicated a signiﬁcant
effect over time (MAP: F(48,392)=26, Pb0.0001; and HR: F(48,392)=
48, Pb0.0001) (Fig. 5).3.2.5. Propranolol
The microinjection of the nonselective β-adrenoceptor antagonist
propranolol (n=5) into the ICdidnot affect eitherMAP(96±3vs. 101±
4mmHg; t=1.5, PN0.05) or HR (356±9 vs. 369±16 bpm, t=0.9,
PN0.05) baseline values. The IC pretreatment with propranolol also did
not change cardiovascular responses to the microinjection of noradren-
aline into the IC (Fig. 5). Two-way ANOVA indicated no signiﬁcant effect
of propranolol on the cardiovascular effects of noradrenaline (MAP:
F(1,392)=0.2, PN0.05; and HR: F(1.392)=2, PN0.05), but indicated a
signiﬁcant effect over time (MAP: F(48,392)=26, Pb0.0001; and HR:
F(48,392)=51, Pb0.0001) (Fig. 5).Fig. 5. Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) e
pretreatment with the selective α2-adrenoceptor antagonist RX821002 (15 nmol/100 n
Noradrenaline injections were made at time 0. Points represent the mean and bars the SEM3.3. Cardiovascular responses to microinjection of phenylephrine into the
IC of unanesthetized rats
Microinjection of phenylephrine (n=5) into the IC (basal MAP:
95±2 mm Hg and basal HR: 373±8 bpm) caused pressor response
(ΔMAP=49±4 mm Hg, t=9.7, Pb0.05), which was accompanied
by bradycardia (ΔHR=−95±4 bpm, t=11, Pb0.05). A typical
recording showing cardiovascular responses to the microinjection
of phenylephrine into the IC of a representative animal is presented
in Fig. 2B.
3.4. Effect of i.v. treatment with saline, pentolinium or dTyr(CH2)5(Me)
AVP on the cardiovascular responses to the microinjection of
noradrenaline into the IC
3.4.1. Saline
The i.v. administration of saline (n=5) did not affect either
pressor (43±2 vs. 45±3 mm Hg; t=0.3, PN0.05) or bradycardiac
(−50±2 vs. −49±3 bpm; t=0.2, PN0.05) responses to the
microinjection of noradrenaline into the IC.
3.4.2. Pentolinium
The i.v. pretreatment with the ganglion blocker pentolinium
(n=5) signiﬁcantly reduced baseline MAP values (98±3 vs. 68±
3 mm Hg, t=5.7, Pb0.05), but did not affect baseline HR values
(364±10 vs. 382±9 bpm; t=0.8, PN0.05). Pretreatment with
pentolinium potentiated the pressor response evoked by the
microinjection of noradrenaline into the IC and blocked the
bradycardiac response (Fig. 6). Two-way ANOVA indicated a signiﬁcant
effect of treatment with pentolinium on the cardiovascular effects of
noradrenaline (MAP: F(1.456)=701, Pb0.0001; and HR: F(1.456)=852,
Pb0.0001); a signiﬁcant effect over time (MAP: F(56.456)=52,
Pb0.0001; and HR: F(56.456)=28, Pb0.0001) and an interactionvoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after IC
L) or the nonselective β-adrenoceptor antagonist propranolol (15 nmol/100 mL).
; two-way ANOVA followed by Bonferroni's post hoc test.
Fig. 6. Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after
intravenous pretreatment with pentolinium (5 mg/kg) or dTyr(CH2)5(Me)AVP (dTyr, 50 μg/kg). Noradrenaline microinjections were made at time 0. Points represent the mean and
bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test.
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F(56.456)=24, Pb0.0001) (Fig. 6).
3.4.3. dTyr(CH2)5(Me)AVP
The i.v. pretreatment with the selective V1-vasopressin receptor
antagonist dTyr(CH2)5(Me)AVP (n=5) did not affect either MAP
(102±3 vs. 97±3 mm Hg, t=1.3, PN0.05) or HR (368±12 vs. 352±
9 bpm, t=0.6, PN0.05) baseline values. Cardiovascular responses to
the microinjection of noradrenaline into the IC were signiﬁcantly
reduced after i.v. treatment with the V1-vasopressin receptor
antagonist (Fig. 6). Two-way ANOVA indicated a signiﬁcant effect of
treatment with dTyr(CH2)5(Me)AVP on the cardiovascular effects of
noradrenaline (MAP: F(1.392)=120, Pb0.0001; and HR: F(1.392)=294,
Pb0.0001); a signiﬁcant effect over time (MAP: F(48.392)=14,
Pb0.0001; and HR: F(48.392)=29, Pb0.0001) and an interaction
between treatment and time (MAP: F(48.392)=6, Pb0.0001; and HR:
F(48.392)=18, Pb0.0001) (Fig. 6).
A photomicrograph of a coronal brain section showing a
representative microinjection site into the IC is presented in Fig. 7.
A diagrammatic representation modiﬁed from Paxinos and Watson
(1997) that indicates microinjection sites of ACSF, noradrenaline,
WB4101, 5-methyl-urapidil, RX821002 and propranolol into the IC
and noradrenaline into areas surrounding the IC is also presented in
Fig. 7.
4. Discussion
In the present study, we report that noradrenaline microinjection
into the IC of unanesthetized rats caused dose-related pressor and
bradycardiac responses. These responses were reduced by IC
pretreatment with either selective α1-adrenoceptor antagonists
WB4101 or 5-methyl-urapidil. Moreover, the IC microinjection of
the selective α1-adrenoceptor agonist phenylephrine evoked pressor
and bradycardiac responses similar those observed after noradrena-
line microinjection. The systemic treatment with the ganglion blockerpentolinium potentiated the pressor response evoked by noradren-
aline and blocked the bradycardiac response, whereas systemic
treatment with the selective V1-vasopressin receptor antagonist
dTyr(CH2)5(Me)AVP reduced both pressor and bradycardiac
responses to noradrenaline microinjected into the IC.
Noradrenergic neural terminals have been identiﬁed in the IC
(Ungerstedt, 1971). These IC innervations are mainly originated from
noradrenergic cells grouped in the LC, which is a small noradrenergic
nucleus (designated as A6), that contains ≈1500 neurons projecting
to several areas of the forebrain, including the IC (Morrison et al.,
1979; Ungerstedt, 1971). The IC noradrenergic synapses are geomet-
rically orderly throughout the lateral neocortex and that organization
differs considerably from that of other cortical afferents. Two
noteworthy features of the noradrenergic innervation are the high
density of ﬁbers throughout all cortical layers and the predominantly
tangential orientation of axons within the cortical gray matter
(Morrison et al., 1978).
Previous results, performed in our laboratory, have demonstrated
that activation of IC α1-adrenoceptors induce an inhibitory inﬂuence
on the cardiac component of the baroreﬂex (Alves et al., 2009a).
Moreover, it has been reported that IC noradrenergic neurotransmis-
sion modulates the cardiovascular responses associated with stress
situations (Funk and Stewart, 1996). These results provide evidences
of a relevant involvement of IC noradrenergic neurotransmission in
central cardiovascular control. Therefore, to investigate the subtype of
adrenoceptor involved with mediation of cardiovascular responses
evoked by microinjection of noradrenaline into the IC, the IC was
pretreated with either selective α1-adrenoceptor antagonists
WB4101 or 5-methyl-urapidil; the selective α2-adrenoceptor
antagonist RX821002 or the nonselective β-adrenoceptor antago-
nist propranolol. The local IC pretreatment with either WB4101 or
5-methyl-urapidil signiﬁcantly reduced the peak and length of the
pressor and bradycardiac responses evoked by noradrenaline micro-
injection into the IC, thus indicating that these responses depend
mainly on local α1-adrenoceptor. IC pretreatment with either
Fig. 7. A photomicrograph of a coronal brain section, from one representative rat, which shows the injection site in the IC. Diagrammatic representation based on the rat
brain atlas of Paxinos and Watson (1997), which indicates injection sites into the IC of ACSF (gray circles), noradrenaline (ﬁlled circles), WB4101 (ﬁlled squares), RX821002
(gray squares), 5-methyl-urapidil (open squares), phenylephrine (gray triangles) or propranolol (ﬁlled triangles) and noradrenaline into structures surrounding the IC (open
circles). Cg1 — cingulate cortex, area; PrL — prelimbic cortex, M1 — primary motor cortex; IC — insular cortex, cc — corpus callosum, forceps minor of the corpus callosum
(fmi).
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evoked by noradrenaline, thus reinforcing the idea of an involvement
of α1-adrenoceptor. Therefore, these results suggest a preferential
mediation via activationof localα1-adrenoceptors on thecardiovascular
responses evoked by microinjection of noradrenaline into the IC.
Similar doses of the antagonists WB4101 and RX821002 have been
previously used to identify the subtype ofα-adrenoceptors whichwere
involved in the mediation of pressor responses to noradrenaline
microinjection in speciﬁc central nervous system (CNS) structures
(Fernandes et al., 2003; Scopinho et al., 2006; Busnardo et al., 2009). The
pressor response to localmicroinjection of noradrenaline into themPFC
or lateral septal area was blocked by the pretreatment with WB4101,
but not by the pretreatment with RX821002, thus suggesting an
involvement of local α1-adrenoceptors (Fernandes et al., 2003;
Scopinho et al., 2006). On the other hand, pressor response to
noradrenalinemicroinjection into the hypothalamic supraoptic nucleus
(SON)was inhibited after local pretreatmentwith RX821002, but not by
treatment with WB4101 (Busnardo et al., 2009), which points to an
involvementofα2-adrenoceptors. Also, their use allowedus to identify a
situation in which both α-adrenoceptors subtypes were involved in
the mediation of pressor responses to noradrenaline microinjected
into the BST (Crestani et al., 2008). These observations indicate that
the dose of WB4101 and RX821002 used in the present study is
selective and effective in demonstrating the predominance of either
α1- or α2-adrenoceptor in responses involving noradrenergic
neurotransmission.
To conﬁrm the involvement of local IC α1-adrenoceptor on the
noradrenaline cardiovascular responses, it was performed in the IC local
administration of the selectiveα1-adrenoceptor agonist phenylephrine.
The administration of phenylephrine into the IC evoked similar changes
on MAP and HR compared to that observed after noradrenaline
microinjection, thus reinforcing the idea thatα1-adrenoceptorsmediatecardiovascular responses to noradrenalinemicroinjected into the IC. It is
important tonote that thedoseofphenylephrinewashigher than thatof
noradrenaline, once that it has been reported that noradrenaline is
approximately 10-times more potent than phenylephrine to evoke
cardiovascular responses when microinjected in the CNS (Correa and
Peres-Polon, 1995).
Changes in arterial pressure, HR and renal sympathetic nerve
activity (RSNA) have been reported after chemical stimulation of the
IC (Butcher and Cechetto, 1995). The IC has been proposed to
modulate the sympathetic nervous activity through a mandatory
synapse in the ventrolateral medulla, since it was reported that the
increase in RSNA evoked by IC stimulation was completely abolished
after ventrolateral medulla treatment with the nonselective synapses
blocker CoCl2 (Butcher and Cechetto, 1995; Cechetto and Chen, 1992).
Consequently, the possible involvement of the sympathetic nervous
system in the mediation of the pressor response observed after the
microinjection of noradrenaline into the IC should be studied.
Systemic pretreatment with ganglion blocker has been traditionally
used as a pharmacological tool to reduce sympathetic nervous activity.
In the present study, systemic treatment with pentolinium signiﬁcantly
lowered basal levels of arterial pressure, conﬁrming its effectiveness in
reducing sympathetic activity. The variation of MAP (ΔMAP) evoked by
IC treatmentwith noradrenalinewas enhanced after ganglion blockade.
However, the increase on ΔMAP was similar to change in MAP
baseline evoked by pentolinium treatment. Therefore, the increase
in ΔMAP caused by microinjection of noradrenaline into the IC
in pentolinium-treated animals may be attributed to the initial
reduction in MAP baseline caused by the ganglion blockade.
Similar increases in pressor responses caused by central injection of
noradrenaline were reported after its injection intracerebroventricular
(i.c.v.) (Correa et al., 1985), into the BST (Crestani et al., 2007), into the
SON (Busnardo et al., 2009) or into themPFC (Fernandes et al., 2003) of
97F.H.F. Alves et al. / Autonomic Neuroscience: Basic and Clinical 160 (2011) 90–98pentolinium-treated rats, thus suggesting a humoral mediation. Under
those conditions, the pressor effect of the central injection of
noradrenaline was reported to be caused by vasopressin release into
the circulation (Busnardo et al., 2009; Correa et al., 1985; Crestani et al.,
2007; Fernandes et al., 2003).
In the CNS α1-adrenoceptors have been shown to mediate
vasopressin release by cathecolamines both in vitro (Randle et al.,
1986; Yamashita et al., 1988) and in vivo (Brooks et al., 1986; Correa
and Peres-Polon, 1995; Crestani et al., 2007). Attempting to verify
whether circulating vasopressin was involved in the pressor response
to noradrenaline microinjected into IC, we pretreated animals with
the selective V1-vasopressin receptor antagonist dTyr(CH2)5(Me)AVP.
This vasopressin antagonist has been previously used to evidence a
vasopressin involvement in the mediation of pressor responses
caused by noradrenaline microinjections either i.c.v. or into speciﬁc
CNS structures (Busnardo et al., 2009; Correa et al., 1985; Crestani
et al., 2007), as well as after the intraseptal microinjection of
acetylcholine (Peres-Polon and Correa, 1994) and the microinjection
of L-glu into the diagonal band of Broca or the SON (Busnardo et al.,
2007; Tavares and de Aguiar Correa, 2003). The peak and length of the
pressor response to noradrenaline microinjection into the IC were
signiﬁcantly reduced after pretreatment with dTyr(CH2)5(Me)AVP,
thus indicating that this response is mainly mediated by an action of
the vasopressin. Thus, this result suggests that pressor response
evoked by microinjection of noradrenaline into the IC involves acute
release of vasopressin into the circulation.
The i.v. treatmentwith either pentolinium or dTyr(CH2)5(Me)AVP
abolished the bradycardiac response to noradrenaline microinjected
into the IC. Together, these data suggest a vagal baroreﬂex response,
as a consequence of MAP increase. Vasopressin has been reported to
cause positive chronotropic effect (Chiba, 1977), thus reinforcing the
idea of a reﬂex bradycardia. Also, there was a good correlation
between MAP increases and bradycardiac responses.
Vasopressin, also known as antidiuretic hormone, is a potent
vasoconstrictor (Altura and Altura, 1984; Barer, 1961). Two different
types of hypothalamic neurons, magnocellular and parvocellular,
synthesize vasopressin. The magnocellular neurons are mainly
located in the SON and paraventricular nucleus (PVN) of the
hypothalamus. Each neuron gives rise to a single axon into the
posterior pituitary gland, where its neurosecretory endings release
vasopressin. Because the capillaries within the pituitary gland lack an
effective blood-brain barrier, vasopressin is released in close proxim-
ity to the capillaries and easily enters the bloodstream (Leng et al.,
1999). No direct connections were observed between the IC and
either the PVN or the SON (Yasui et al., 1991), thus suggesting the
existence of a relay in this pathway. Thus, the IC should be linked to
the PVN or SON through an indirect projection. The microinjection of
noradrenaline into the BST has been reported to cause pressure and
bradycardiac responses, which are mediated by vasopressin release
into the circulation (Crestani et al., 2008, 2007; Crestani et al., 2009).
Also, neuronal connections have been identiﬁed between the IC and
the BST (Yasui et al., 1991), as well as between the BST and the PVN
and SON (Dong and Swanson, 2004). Considering this, the connection
between the IC and the hypothalamus could be the BST. However,
further studies are necessary to clarify the pathway involved in these
responses.
The physiological role of this pressor pathway activated by the
microinjection of noradrenaline into the IC is not yet clear.
Vasopressin release is stimulated by plasma osmolality increase,
arterial pressure decrease and by reduced cardiac ﬁlling or changes in
blood volume (Goldsmith, 1988). Therefore, we may hypothesize that
a noradrenergic mechanism in the IC can integrate cardiovascular and
neuroendocrine control and could take part in ﬂuid balance and
cardiovascular adjustments to stress responses. This idea is favored by
studies indicating that brainstem noradrenergic cell groups are
activated during stress (Chen and Herbert, 1995; Dayas et al., 2001).IC treatment with adrenoceptor antagonists did not affect either
MAP or HR baseline values. Thus, although the present study
supports the idea that an IC noradrenergic neurotransmission
modulates the cardiovascular system, this neurotransmission is not
involved in the tonic maintenance of either arterial pressure or HR.
These results corroborate previous data indicating no changes in
cardiovascular parameters after IC lesions, local synaptic blockade,
blockade of glutamate receptors or blockade of adrenoceptors
(Alves et al., 2009a,b; Zhang et al., 1998).
In summary, the administration of noradrenaline into the IC
caused pressor responses, which was accompanied by bradycardia in
unanesthetized rats. Our data suggest that bradycardiac response is a
vagal baroreﬂex response, as a consequence of MAP increase. Because
noradrenaline effects caused by activation of IC α1-adrenoceptors
were mediated by acute vasopressin release into the circulation, the
results suggest that IC noradrenergic neurotransmission plays a role in
the neural circuitry that regulates neuroendocrine and cardiovascular
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